No material discrete news events were available in verified briefings for the 30-day period preceding this report's generation date. Prior briefings on record noted Pfizer's trailing twelve-month revenue figure as consistent across recent reporting periods, and the current data set aligns with that picture [Brief - 2026-09-27] [Brief - 2026-09-19] [Brief - 2026-09-11]. The absence of confirmed news items in the briefing record means this report draws primarily from SEC filing data, institutional holdings disclosures, and macroeconomic indicators.
As of the quarter ending 2026-06-28, Pfizer reported trailing twelve-month revenue of $63.70 billion, representing year-over-year growth of 2.60%. Net income over the same period was $4.33 billion, with a net margin of 6.80% and an operating margin of 35.19%. Earnings per share declined 107.84% year-over-year. The company held $976 million in cash against total debt of $63.19 billion. The price-to-earnings ratio stood at 36.58 [SEC 10-Q - PFE - 2026-06-28].
Several institutional investors reported material changes to their PFE positions in the most recent 13F filings. Citadel added 15% to its existing position, Millennium added 28%, and AQR Capital added 56% to its position. Bridgewater opened a new position in the stock. No insider transaction data from SEC Form 4 filings was available in the provided context for this reporting period [SEC 13F - Citadel - Q3 2026] [SEC 13F - Millennium - Q3 2026] [SEC 13F - AQR Capital - Q3 2026] [SEC 13F - Bridgewater - Q3 2026].
The prevailing macroeconomic interest rate environment shows the 10-year US Treasury yield at 5.24% and the 2-year yield at 4.78%, reflecting a normal yield curve configuration [FRED DGS10] [FRED DGS2]. This rate environment is relevant context for a company carrying $63.19 billion in total debt against $976 million in cash, as borrowing costs and refinancing conditions remain a structural factor in Pfizer's financial profile. The material institutional position increases across multiple large allocators served as the primary trigger for this report.